ESPR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Esperion Therapeutics, Inc.

NEW YORK--()--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Esperion Therapeutics, Inc. (“Esperion” or the “Company”) (NASDAQGM: ESPR) violated federal securities laws.

Click here to learn about the case: http://www.wongesq.com/pslra-c/esperion-therapeutics-inc. There is no cost or obligation to you.

On May 2, 2018, Esperion announced results from its second Phase 3 study for its cholesterol-lowering medication bempedoic acid. Esperion reported that while the trial met the primary endpoint of safety and tolerability and the key efficacy endpoint, there were 13 deaths in the treatment group compared to only two in the control group. On this news, Esperion’s share price fell from a close of $70.50 per share on May 1, 2018, to a close of $45.75 per share the following day.

To learn more about the investigation of Esperion contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-c/esperion-therapeutics-inc.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

The Law Offices of Vincent Wong
Vincent Wong, Esq., 212-425-1140
Fax. 866-699-3880
vw@wongesq.com

Release Summary

The Law Offices of Vincent Wong notifies investors in Esperion of a class action.

Contacts

The Law Offices of Vincent Wong
Vincent Wong, Esq., 212-425-1140
Fax. 866-699-3880
vw@wongesq.com